Long-term effects of cariprazine exposure on dopamine receptor subtypes

CNS Spectrums

Volumn 19, Issue 3, 2014, Pages 268-277

  Choi, Yong Kee ^a   Adham, Nika ^b   Kiss, Béla ^c   Gyertyán, István ^c   Tarazi, Frank I ^a  

^a MCLEAN HOSPITAL   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c GEDEON RICHTER LTD   (Hungary)

Author keywords

Antipsychotic drugs; autoradiography; cariprazine; dopamine receptors; schizophrenia

Indexed keywords

CARIPRAZINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN TISSUE; CAUDATE PUTAMEN; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HIPPOCAMPUS; LONG TERM EXPOSURE; MALE; MEDIAL PREFRONTAL CORTEX; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; OLFACTORY NERVOUS SYSTEM; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR UPREGULATION; TISSUE SECTION; BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; IN VITRO STUDY; LOW DRUG DOSE; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TREATMENT DURATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; BRAIN; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PIPERAZINES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; TETRAHYDRONAPHTHALENES; TRITIUM;

EID: 84902209729     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000680     Document Type: Article

References (53)

1. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker K, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill Press; 2005: 461-500.
2. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011; 63(1): 182-217.
3. Baldessarini RJ, Tarazi FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry. 1996; 3(6): 301-325. (Pubitemid 26141569)
4. Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol. 2011; 7(7): 829-846.
5. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16(5): 488-501.
6. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998; 18(2): 63-101. (Pubitemid 28026679)
7. Biedermann F, FleischhackerWW. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs. 2011; 16(2): 271-282.
8. Waddington JL, Casey D. Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Waddington JL, Buckley PF, eds. Schizophrenia and Mood Disorders. Oxford, UK: Butterworth-Heinemann; 2000: 1-13.
9. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl). 2008; 198(1): 103-111.
10. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001; 297(2): 711-717. (Pubitemid 32378004)
11. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2003; 306(3): 1145-1151. (Pubitemid 37025325)
12. Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse. 2009; 63(5): 413-420.
13. Tarazi FI, Florijn WJ, Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology (Berl). 1996; 128(4): 371-379. (Pubitemid 26417679)
14. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol. 2010; 24(3): 341-348.
15. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl). 2002; 161(3): 263-270. (Pubitemid 34591664)
16. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev. 2008; 60(3): 358-403.
17. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010; 333(1): 328-340.
18. Bose A, Li D, Migliore R, et al. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Paper presented at: New Clinical Drug Evaluation Unit (NCDEU)-50th Annual Meeting; June 14-17, 2010; Boca Raton, FL.
19. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. Feb. 2013; 30(2): 114-126.
20. Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013; 30(2): 102-113.
21. Knesevich MA, Papadakis K, Bose A, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a Phase II trial. Paper presented at: American Psychiatric Association (APA)-162nd Annual Meeting; May 16-21, 2009; San Francisco, CA.
22. Starace A, Bose A, Wang Q, et al. Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, Phase III trial. Paper presented at: American Psychiatric Association (APA)-165th Annual Meeting; May 5-9, 2012; Philadelphia, PA.
23. Cutler AJ, Bose A, Durgam S, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week extension study. Paper presented at: American Psychiatric Association (APA)-165th Annual Meeting; May 5-9, 2012; Philadelphia, PA.
24. Gyertyán I, Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011; 59(6): 925-935.
25. Kiss B, Horti F, Bobok A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res. 2012; 136(Suppl 1): S190.
26. Kirschner N, Gémesi LI, Vastag M, et al. In vitro metabolism of RGH-188. Drug Metab Rev. 2008; 40(Suppl 1): 128-129.
27. Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012.213: 167-210.
28. Cho DI, Zheng M, Kim KM. Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors. Arch Pharm Res. 2010; 33(10): 1521-1538.
29. Laszy J, Laszlovszky I, Gyertyán I. Dopamine D(3) receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl). 2005; 179(3): 567-575. (Pubitemid 40674757)
30. Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs. 2009; 23(10): 837-855.
31. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd ed. Sydney: Academic Press; 1986.
32. Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther. 1997; 280(2): 561-569. (Pubitemid 27171313)
33. Tarazi FI, Kula NS, Baldessarini RJ. Regional distribution of dopamine D4 receptors in rat forebrain. Neuroreport. 1997; 8(16): 3423-3426. (Pubitemid 27497456)
34. Greene WH. Econometric analysis, 4th ed. Upper Saddle River, NJ: Prentice Hall; 2000.
35. Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design, 3rd ed. New York: McGraw-Hill; 1991.
36. Tarazi FI, Florijn WJ, Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience. 1997; 78(4): 985-996. (Pubitemid 27223705)
37. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL. Long-term effects of S(1)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology. 1997; 17(3): 186-196. (Pubitemid 27365959)
38. de Beaurepaire R, Labelle A, Naber D, Jones BD, Barnes TR. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology (Berl). 1995; 121(3): 323-327.
39. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci. 2007; 27(42): 11424-11430. (Pubitemid 47621327)
40. Krieckhaus EE, Donahoe JW, Morgan MA. Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry. 1992; 31(6): 560-570.
41. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989; 12(10): 366-375. (Pubitemid 19238787)
42. Kleven MS, Barret-Grevoz C, Bruins Slot L, Newman-Tancredi A. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology. 2005; 49(2): 135-143. (Pubitemid 40933752)
43. Bardin L, Kleven MS, Barret-Grevoz C, Depoortere R, Newman-Tancredi A. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology. 2006; 31(9): 1869-1879.
44. Zhang K, Weiss NT, Tarazi FI, Kula NS, Baldessarini RJ. Effects of alkylating agents on dopamine D(3) receptors in rat brain: selective protection by dopamine. Brain Res. 1999; 847(1): 32-37. (Pubitemid 29516702)
45. Kiss B, Horti F, Bobok A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Paper presented at: 3rd Biennial Schizophrenia International Research Society Congress; April 14-18, 2012; Florence, Italy.
46. Sokoloff P, Guillin O, Diaz J, Carroll P, Griffon N. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders. Neurotox Res. 2002; 4(78): 671-678. (Pubitemid 35390310)
47. Dias VV, Balanza-Martinez V, Soeiro-de-Souza MG, et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand. 2012; 126(5): 315-331.
48. Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord. 2010; 12(4): 364-375.
49. Gyertyán I, Sághy K, Laszy J, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008; 378(5): 529-539.
50. Millan MJ, Loiseau F, Dekeyne A, et al. S33138 (N-[4-[2-[(3aS,9bR)-8- cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl- acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther. 2008; 324(3): 1212-1226.
51. Micale V, Cristino L, Tamburella A, et al. Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol Res. 2010; 61(6): 531-536.
52. Corrigan MH, Gallen CC, Bonura ML, Merchant KM. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry. 2004; 55(5): 445-451. (Pubitemid 38338530)
53. Kramer MS, Last B, Getson A, Reines SA. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry. 1997; 54(6): 567-572. (Pubitemid 27258555)